Fetal aneuploidy detection by maternal plasma DNA sequencing: a technology assessment
Open Access
- 17 May 2013
- journal article
- review article
- Published by Wiley in Prenatal Diagnosis
- Vol. 33 (6) , 514-520
Abstract
The American College of Obstetricians and Gynecologists currently recommends that all pregnant women be offered screening for chromosomal abnormalities, regardless of maternal age. Traditional screening tests have detection rates ranging from 85% to 90% and false‐positive rates of 3% to 5%. A woman with an abnormal noninvasive test is offered a diagnostic test, but diagnostic tests are associated with a risk of pregnancy loss. Recently, analysis of cell‐free fetal DNA (cffDNA) in maternal blood has been shown to have potential for the accurate detection of some of the common fetal autosomal aneuploidies. As part of a technology assessment for the California Technology Assessment Forum, we critically reviewed the evidence for the use of cffDNA as a prenatal screening test. We evaluated the evidence for its use as either a ‘primary’ or an ‘advanced’ screening test and for its use in screening for three different trisomies: 21, 18, and 13. We evaluated whether the use of cffDNA met established technology assessment criteria and established conclusions about evidence‐based use of this new technology. © 2013 John Wiley & Sons, Ltd.Keywords
This publication has 16 references indexed in Scilit:
- Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18American Journal of Obstetrics and Gynecology, 2012
- Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18American Journal of Obstetrics and Gynecology, 2012
- DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative studyGenetics in Medicine, 2012
- DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation studyGenetics in Medicine, 2011
- Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity studyBMJ, 2011
- Screening for fetal aneuploidies at 11 to 13 weeksPrenatal Diagnosis, 2011
- Prenatal screening for open neural tube defects and Down syndrome: three decades of progressPrenatal Diagnosis, 2010
- Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected populationAmerican Journal of Obstetrics and Gynecology, 2006
- First-Trimester or Second-Trimester Screening, or Both, for Down's SyndromeNew England Journal of Medicine, 2005
- The Blue Cross Blue Shield Association Technology Evaluation Center: How we evaluate radiology technologiesJournal of the American College of Radiology, 2005